



Tufts Center for the Study of Drug Development

TUFTS UNIVERSITY

Impact REPORT

ANALYSIS AND INSIGHT INTO CRITICAL DRUG DEVELOPMENT ISSUES

Comparative effectiveness research impacts patient access to cancer drugs

Tufts CSDD study compares access to cancer drugs in the U.S. and Australia

- Oncology drug approvals in the U.S. outpaced Australian approvals by more than 60%.
- Regulatory approval in Australia does not necessarily lead to reimbursement, as the threshold for reimbursement is higher, i.e., it is based on comparative effectiveness evidence.
- Australia imposes greater restrictions than the U.S. on reimbursement of oncology drugs.
- Patient cost sharing is significantly lower in Australia than the U.S.
- Oncology drug prices in Australia average 30% less than in the U.S., due in part to value-based pricing, which is linked to comparative effectiveness research.
- Australia, the first country to adopt a formal set of regulatory procedures to make coverage decisions based partly on cost-effectiveness, has been emulated by others.